ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > COMP

COMP

概要

Name:Sodium channel protein type VIII alpha subunit
Target Synonym:MYOCL2,Sodium Channel, Voltage Gated, Type VIII, Alpha Subunit,Sodium Channel, Voltage Gated, Type VIII Alpha Subunit,NAV1.6 Voltage-Gated Sodium Channel,Sodium channel protein type 8 subunit alpha,Sodium channel protein type VIII subunit alpha,MED,SCN8A,Sodium Voltage-Gated Channel Alpha Subunit 8,Voltage-Gated Sodium Channel Subunit Alpha Nav1.6,Sodium Channel, Voltage Gated, Type VIII, Alpha Polypeptide,Voltage-Gated Sodium Channel Type VIII Alpha Protein,HNa6/Scn8a Voltage-Gated Sodium Chann
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
COP-H5220 Human Human COMP / TSP5 Protein, His Tag
COP-H5220-structure
COP-H5220-sds
ACRO Quality

Synonym Name

COMP,TSP5,EDM1,EPD1,MED,PSACH,THBS5

Background

Cartilage oligomeric matrix protein (COMP) is also known as Thrombospondin-5 (TSP5), EDM1, EPD1, MED, PSACH, THBS5, which belongs to the thrombospondin family. COMP / TSP5 contains 4 EGF-like domains, 1 TSP C-terminal (TSPC) domain, 8 TSP type-3 repeats. Abundantly expressed in the chondrocyte extracellular matrix, and is also found in bone, tendon, ligament and synovium and blood vessels. COMP may play a role in the structural integrity of cartilage via its interaction with other extracellular matrix proteins such as the collagens and fibronectin. COMP can mediate the interaction of chondrocytes with the cartilage extracellular matrix through interaction with cell surface integrin receptors. Thrombospondin-5 could play a role in the pathogenesis of osteoarthritis. COMP is a marker of cartilage turnover.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Pirmenol Hydrochloride CI-845 Approved Sumitomo Dainippon, Pfizer Inc Pimavar, Pimenol Japan Arrhythmias, Cardiac null 1994-01-01 Arrhythmias, Cardiac Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
XEN-901 NBI-921352; XEN-901 Phase 2 Clinical Xenon Pharma Seizures; Epilepsies, Partial; Brain Diseases; Epilepsy Details
PRAX-562 PRAX-562 Phase 2 Clinical Praxis Precision Medicines Brain Diseases; Epilepsy Details
PRAX-330 GS-458967; GS-967; PRAX-330 Phase 1 Clinical Praxis Precision Medicines Inc Epilepsy Details

This web search service is supported by Google Inc.

totopphone